Beaverton Teacher’s Cancer Treatment Unblocked After Community Pressure on Insurer

Key points

• Niki Taylo, a teacher at Beaverton’s Sunset High School, was diagnosed with Stage IV endometrial cancer in 2024, but recent scans showed mixed results with some tumors growing.
• Her oncologist at OHSU recommended ENHERTU, a targeted therapy, but Regence Blue Cross Blue Shield denied coverage twice, leaving her without treatment for seven weeks.
• The out-of-pocket cost for ENHERTU is over $63,000 per three-week cycle, and the Taylos were denied financial assistance through the ENHERTU4U program due to income limits.
• A GoFundMe campaign raised more than $75,000 in one week, supported by former students and a coordinated email campaign to the insurer.
• Regence subsequently agreed to cover the medication through the ENHERTU4 program, though the appeal is still moving through independent review channels.
• Taylo’s first treatment is scheduled for Friday, and the family intends to use the fundraiser proceeds for additional care outside the United States.

Background

This case highlights recurring issues in cancer care access, where insurance denials for targeted therapies create dangerous gaps between medical recommendations and coverage. Similar patterns were seen in September 2026 when a Texas teen died after insurers denied coverage for a rare brain cancer drug, and when FDA-approved pancreatic cancer drugs faced reimbursement delays. These incidents underscore the tension between clinical evidence and payer policies, often forcing patients to rely on community fundraising or third-party appeals to secure necessary treatments.

Why it matters

The case of Niki Taylo illustrates the severe consequences of insurance denials for targeted cancer therapies, where delays can lead to tumor progression and financial ruin. It demonstrates how community mobilization can sometimes override bureaucratic barriers, but also reveals the systemic inefficiencies that force patients to fight for basic care. The incident underscores the need for clearer guidelines in insurance coverage for emerging treatments, reducing the reliance on public pressure for individual cases.

What to watch

Niki Taylo is scheduled to begin her first round of ENHERTU treatment on Friday. The Taylos plan to use the funds raised from the GoFundMe campaign to access additional care outside the United States. Meanwhile, Regence Blue Cross Blue Shield is processing the appeal through the Independent Review Organization, and the family awaits a final confirmation of coverage status.